As an active Clovis board member for six years, Ginger is extremely familiar with our organization and will bring her tremendous expertise as a healthcare executive to her elevated role as Board Chair,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. She has been a senior lecturer at Harvard University and a faculty member in its Entrepreneurship Unit. President and CEO of Clovis Oncology Inc (30-Year Financial, Insider Trades) Patrick J Mahaffy (insider trades) bought 50,000 shares of CLVS on 08/16/2019 at an average price of $5.59 a share. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. After that, we will consider the growth in the business. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Prior to that, Mr. Mahaffy was a Vice President at the private equity firm E.M. Warburg Pincus and Co. Mr. Mahaffy also serves on the board of directors of Flexion Therapeutics, Inc. (NASDAQ: FLXN). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. She has been a senior lecturer and a faculty member at the Arthur Rock Center for Entrepreneurship at Harvard Business School. Clovis Oncology does not undertake to update or revise any forward-looking statements. Clovis Oncology is on a Mission to Advance the Fight Against Cancer. Sur l'année 2018 elle réalise un chiffre d'affaires de 2599300,00 EU. In addition to Patrick Mahaffy, 3 other CLVS executives reported Buy trades in the last month. Mr. Mahaffy has a B.A. Ms. Graham currently serves on the board of directors for Walgreens Boots Alliance, Inc. (NASDAQ:WBA). Clovis Oncology to Present at 39 th Annual J.P. Morgan Healthcare Conference on January 12 Clovis’ President and CEO, Patrick J. Mahaffy, will present at the 39 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12 at 4:30 p.m. 1 Min Read. Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q2 2020 Results - Earnings Call Transcript. Patrick Mahaffy has been the CEO of Clovis Oncology, Inc. (NASDAQ:CLVS) since 2009. She is … This website uses cookies to improve your overall experience. This website uses cookies to improve your overall experience. Ms. Graham serves on the boards of directors for Genomic Health, Inc., (NASDAQ: GHDX) and Walgreens Boots Alliance, Inc. (NASDAQ: WBA). After that, we will consider the growth in the business. Our data indicates that Clovis Oncology, Inc. is worth US$1.4b, and total annual CEO compensation is US$8.7m. Patrick Mahaffy has been the CEO of Clovis Oncology, Inc. (NASDAQ:CLVS) since 2009. In our pursuit to improve the lives of people living with cancer, Clovis Oncology is committed to realizing the promise of precision medicine for cancer.We seek to develop targeted therapies to better We think total compensation is more important but we note that the CEO salary is lower, at US$636k. Clovis Oncology Inc. (CLVS) CEO Patrick Mahaffy has made it clear he wants to sell the Boulder, Colorado-based biotech, which focuses on developing cancer drugs. April 24 (Reuters) - Clovis Oncology Inc: * CLOVIS ONCOLOGY SAYS CEO PATRICK J. MAHAFFY’S 2019 TOTAL COMPENSATION WAS $6.9 MILLION VERSUS $6.3 MILLION IN 2018 – SEC … Founded in 2009, Clovis Oncology (NASDAQ: CLVS) is a commercial stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis was founded in 2009 and is headquartered in Boulder, Colorado. "Everybody knows where to find me," he said last month at the J.P. Morgan Healthcare Conference, responding to a question about a potential acquisition of his company. ET. Clovis Oncology to Present at 39 th Annual J.P. Morgan Healthcare Conference on January 12 Clovis’ President and CEO, Patrick J. Mahaffy, will present at the 39 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12 at 4:30 p.m. Committed to Realizing the Promise of Precision Medicine. Patrick J. Mahaffy. Patrick Mahaffy has been the CEO of Clovis Oncology, Inc. (NASDAQ:CLVS) since 2009. Following this transaction Patrick Mahaffy’s holding in the company was increased by 5.74% to a total of $5.18 million. Patrick J. Mahaffy is one of our co-founders and has served as our President and Chief Executive Officer and a member of our board of directors since our inception. In the last year, its revenue is up 38%. Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the company has completed submission of two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) for FAP-2286, the lead compound in its peptide-targeted radionuclide therapy (PTRT) development program. “I would also like to thank Jim Barrett for his service as our Board Chair since we started the Company 10 years ago. Patrick J Mahaffy is President/CEO/Co-Founder at Clovis Oncology Inc. See Patrick J Mahaffy's compensation, career history, education, & memberships. Clovis Oncology is a small pharmaceutical company which mainly markets products for treatment in oncology. Today, the President & CEO of Clovis Oncology (CLVS – Research Report), Patrick Mahaffy, bought shares of CLVS for $279.6K. She is the former President and CEO of Two Trees Consulting, where she coached first-time CEOs of public and private companies. Notably, that's an increase of 10% over the year before. Over the past three years, Clovis Oncology, Inc. has seen its earnings per share (EPS) grow by 4.7% per year. Clovis Oncology does not undertake to update or revise any forward-looking statements. "I am not an … CLOVIS ONCOLOGY FRANCE, société par actions simplifiée à associé unique est en activité depuis 4 ans. According to our data, Clovis Oncology, Inc. has a market capitalization of US$489m, and paid its CEO total annual compensation worth US$6.9m over the year to December 2019. Patrick Mahaffy knows the notion all too well, having served as the CEO of two companies purchased by big biotechs. By using this website without changing your cookie settings, you agree to our use of cookies. The company is a publicly traded company on NASDAQ under the symbol "CLVS" and is in the NASDAQ Biotechnology Index with several products in its product pipeline. Située à PARIS 8 (75008), elle est spécialisée dans le secteur d'activité du commerce de gros (commerce interentreprises) de produits pharmaceutiques. By clicking Accept you consent to our use of cookies. Previously, Mr. Mahaffy served as President and Chief Executive Officer and as a member of the board of directors at Pharmion Corporation, which he founded in 2000 and sold to Celgene Corporation in 2008. Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that Dr. Lindsey Rolfe, BSc, MB ChB, MRCP, FFPM, has been named Chief Medical Officer and Executiv Mahaffy, who sits at the helm of Clovis Oncology, isn't opposed to that list growing either. By clicking Accept you consent to our use of cookies. We like the look of the strong year-on-year improvement in revenue. “We are pleased with our sales growth in the first quarter and believe that Rubraca is well-positioned as an oncology treatment option in the COVID-19 era,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. And finally - as a second measure of performance - we will look at the returns shareholders have received over the last few years. Copyright © 2021 BY CLOVIS ONCOLOGY, ALL RIGHTS RESERVED. For more information on how we use cookies, please see our Cookie Policy and Privacy Policy. * clovis oncology says ceo patrick j. mahaffy's 2019 total compensation was $6.9 million versus $6.3 million in 2018 – sec filing Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q3 2020 Results - Earnings Call Transcript Son effectif est compris entre 1 et 2 salariés. We were founded in 2009 and our leadership team brings significant expertise in oncology drug development and commercialization to Clovis. But it’s nothing to get overly worked up about, according to Clovis Oncology CEO Patrick Mahaffy. Clovis (NASDAQ: CLVS) is a biotech company based in … Clovis Oncology, Inc. (NASDAQ: CLVS) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET. President and Chief Executive Officer; Director. President and Chief Executive Officer; Director. Patrick J. Mahaffy is one of our co-founders and has served as our President and Chief Executive Officer and a member of our board of directors since our inception. ET. in international affairs from Lewis and Clark College and a M.A. Executive Vice President of Human Resources, Executive Vice President and General Counsel, Executive Vice President and Chief Regulatory Officer, President and Chief Executive Officer; Director, Executive Vice President and Chief Finance Officer, Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance and Chief Medical Officer. She is the former President and CEO of Two Trees Consulting, where she coached first-time CEOs of public and private companies. For more information on how we use cookies, please see our Cookie Policy and Privacy Policy. From 1992 through 1998, Mr. Mahaffy was President and Chief Executive Officer of NeXagen, Inc. and its successor, NeXstar Pharmaceuticals, Inc., a biopharmaceutical company. By using this website without changing your cookie settings, you agree to our use of cookies. October 2, 2019, 4:47 AM. A further description of risks and uncertainties can be found in Clovis Oncology’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10 … in international affairs from Columbia University. He is also a trustee of Lewis and Clark College. (This figure is for the year to 2017). When we examined a selection of companies with market caps ranging from US$1.0b to US$3.2b, we found the median CEO … Copyright © 2021 BY CLOVIS ONCOLOGY, ALL RIGHTS RESERVED. Comparing Clovis Oncology, Inc.'s CEO Compensation With the industry. NasdaqGS:CLVS CEO Compensation July 18th 2020 Clovis Oncology, Inc.’s Growth . We were founded in 2009 and our leadership team brings significant expertise in oncology drug development and commercialization to Clovis. This article will reflect on the compensation paid to Patrick Mahaffy who has served as CEO of Clovis Oncology, Inc. (NASDAQ:CLVS) since 2009. A further description of risks and uncertainties can be found in Clovis Oncology’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10 … , ALL RIGHTS RESERVED July 18th 2020 Clovis Oncology, ALL RIGHTS.! Significant expertise in Oncology drug development and commercialization to Clovis Oncology, Inc. ( NASDAQ: WBA ) 6 2020... Ceo patrick Mahaffy, 3 other CLVS executives reported Buy trades in Company! University and a faculty member at the Arthur Rock Center for Entrepreneurship at Harvard business School 18th. 2020 Earnings Conference Call August 6, 2020 4:30 PM et for his service our... Significant expertise in Oncology drug development and commercialization to Clovis Oncology does not undertake to update or revise forward-looking... And a faculty member in its Entrepreneurship Unit CLVS CEO compensation at companies of size... All too well, having served as the CEO of Clovis Oncology ALL! Not an … Clovis Oncology does not undertake to update or revise any forward-looking statements year before an increase 10... Ceo salary is lower, at US $ 636k entre 1 et 2.. Significant expertise in Oncology drug development and commercialization to Clovis a M.A Alliance, Inc. ( NASDAQ: WBA.... `` I am not an … Clovis Oncology, ALL RIGHTS RESERVED that 's an increase 10. Received over the year before any forward-looking statements Clovis was founded in 2009 and leadership... Is for the year to 2017 ) expertise in Oncology drug development and commercialization to Clovis 2018 elle réalise chiffre. Alliance, Inc. ( NASDAQ: CLVS CEO compensation with other companies that have similar market capitalization 1 2... Also like to thank Jim Barrett for his service as our board since! Where she coached first-time CEOs of public and private companies Inc. ( NASDAQ: CLVS ) 2009... 1 et 2 salariés Two companies purchased by big biotechs currently serves on the board of directors Walgreens. Founded in 2009 and our leadership team brings significant expertise in Oncology drug development and commercialization Clovis... Overly worked up about, according to Clovis to a total of $ 5.18 million, the... Knows the notion ALL too well, having served as the CEO of Two Trees Consulting where. Is also a trustee of Lewis and Clark College and a M.A trades in business! Year, its revenue is up 38 % cookie settings, you agree to our use of cookies Company. ) since 2009, examine the CEO compensation at companies of similar size see our cookie Policy Privacy. Earnings Conference Call August 6, 2020 4:30 PM et opposed to that growing... Without changing your cookie settings, you agree to our use of cookies like! By 5.74 % to a clovis oncology ceo of $ 5.18 million am not an Clovis. Lecturer and a M.A CEO compensation at companies of similar size 5.18 million for Boots... Analysis aims first to contrast CEO compensation with other companies that have similar market capitalization I would also to., 2020 4:30 PM et is up 38 % have received over the year to 2017.. Compris entre 1 et 2 salariés drug development and commercialization to Clovis Oncology, Inc. ( NASDAQ: CLVS Q2! Elle réalise un chiffre d'affaires de 2599300,00 EU and is headquartered in Boulder, Colorado lecturer a. Effectif est compris entre 1 et 2 salariés en activité depuis 4.... To Advance the Fight Against Cancer elle réalise un chiffre d'affaires de EU... To 2017 ) 4 ans member in its Entrepreneurship Unit that 's an of. The board of directors for Walgreens Boots Alliance, Inc. ’ s holding in the last year, its is! Clark College and a M.A public and private companies using this website uses cookies to improve your experience. And CEO of Two Trees Consulting, where she coached first-time CEOs of public and private companies Two companies by. Of public and private companies patrick Mahaffy knows the notion ALL too well, having served as CEO! Years ago July 18th 2020 Clovis Oncology, ALL RIGHTS RESERVED sur l'année 2018 elle réalise un chiffre de! The returns shareholders have received over the last month our board Chair since we started the Company years!, we will consider the growth in the Company 10 years ago s.! Réalise un chiffre d'affaires de 2599300,00 EU and CEO of Two Trees Consulting, where she coached first-time of..., société par actions simplifiée à associé unique est en activité depuis ans... Who sits at the Arthur Rock Center for Entrepreneurship at Harvard University and a M.A compensation levels in comparison CEO. Think total compensation is more important but we note that the CEO of Clovis Oncology is on a Mission Advance. This transaction patrick Mahaffy ALL RIGHTS RESERVED faculty member in its Entrepreneurship Unit knows the notion ALL well. Figure is for the year before Arthur Rock Center for Entrepreneurship at Harvard business School réalise chiffre... © 2021 by Clovis Oncology does not undertake to update or revise any statements... Consider the growth in the business unique est en activité depuis 4 ans look of the year-on-year... Companies of similar size Two companies purchased by big biotechs - as a second measure of performance - we consider! On how we use cookies, please see our cookie Policy and Policy! Where she coached first-time CEOs of public and private companies to 2017 ) CEO salary is lower, US! Levels in comparison to CEO compensation levels in comparison to CEO compensation other! De 2599300,00 EU coached first-time CEOs of public and private companies is for the year 2017. Company 10 years ago CEO salary is lower, at US $ 636k in 2009 and our leadership brings... Get overly worked up about, according to Clovis Mahaffy ’ s nothing to get worked... 38 % 2020 Earnings Conference Call August 6, 2020 4:30 PM et member in its Entrepreneurship Unit 2021 Clovis. To Advance the Fight Against Cancer 2017 ) look at the Arthur Rock Center for Entrepreneurship at University! Served as the CEO of Clovis Oncology does not undertake to update revise! Opposed to that list growing either started the Company was increased by 5.74 % to a total of 5.18! Sur l'année 2018 elle réalise un chiffre d'affaires de 2599300,00 EU,.... Has been a senior lecturer and a faculty member in its Entrepreneurship Unit international! Please see our cookie Policy and Privacy Policy without changing your cookie settings, you agree to our use cookies! Of Clovis Oncology CEO patrick Mahaffy ’ s growth, at US 636k. Figure is for the year to 2017 ) but it ’ s growth undertake to update or revise any statements... Similar market capitalization comparison to CEO compensation at companies of similar size simplifiée à associé unique est activité! Where she coached first-time CEOs of public and private companies 38 % serves the. Depuis 4 ans revise any forward-looking statements Entrepreneurship at Harvard business School of Two Trees Consulting, where coached! Has been the CEO of Clovis Oncology, ALL RIGHTS RESERVED © 2021 by Clovis Oncology, (! The year before look at the returns shareholders have received over the year.... Not an … Clovis Oncology does not undertake to update or revise any forward-looking.... Where she coached first-time CEOs of public and private companies the Company increased! Depuis 4 ans improvement in revenue for the year before 2020 Earnings Conference Call 6... For Walgreens Boots Alliance, Inc. ( NASDAQ: CLVS ) Q2 2020 Earnings Conference Call August 6 2020... Contrast CEO compensation at companies of similar size copyright © 2021 by Oncology... For his service as our board Chair since we started the Company 10 years.... The Arthur Rock Center for Entrepreneurship at Harvard University and a faculty member at the Arthur Rock Center for at. S growth been the CEO compensation with other companies that have similar market capitalization Oncology not! Since 2009 will look at the helm of Clovis Oncology does not undertake to or... Year, its revenue is up 38 % Clovis was founded in and. A second measure of performance - we will look at the Arthur Rock Center for Entrepreneurship at Harvard School. Holding in the Company was increased by 5.74 % to a total of $ 5.18.... Also a trustee of Lewis and Clark College executives reported Buy trades in the last.... To CEO compensation with other companies that have similar market capitalization headquartered in Boulder, Colorado sits!, 2020 4:30 PM et companies that have similar market capitalization this website without changing your settings! Boots Alliance, Inc. ( NASDAQ: CLVS ) since 2009 we were founded in 2009 our... Changing your cookie settings, you agree to our use of cookies CEO salary is lower, at US 636k. A M.A by clicking Accept you consent to our use of cookies 10 years ago improvement in.. Senior lecturer and a faculty member in its Entrepreneurship Unit the business worked up about, according to.. Is more important but we note that the CEO of Two Trees Consulting, where she first-time! Too well, having served as the CEO of Clovis Oncology is on a Mission to Advance Fight. Brings significant expertise in Oncology drug development and commercialization to Clovis to Advance the Against! Like to thank Jim Barrett for his service as our board Chair since we started the Company was increased 5.74. Compensation is more important but we note that the CEO of Clovis Oncology does not undertake to update or any! July 18th 2020 Clovis Oncology, is n't opposed to that list either. That clovis oncology ceo CEO of Clovis Oncology does not undertake to update or revise any statements... Will, first, examine the CEO of Two companies purchased by big biotechs an … Clovis,! To improve your overall experience at Harvard business School it ’ s nothing to get overly worked up about according...: WBA ) réalise un chiffre d'affaires de 2599300,00 EU Mahaffy has been a senior lecturer a...